Tag Archives: ALL ORDINARIES S&P/ASX Emerging Companies Index

Why we think Somnomed Limited shares can soar higher?

Strong Q4 growth across geographies: SomnoMed Limited (ASX: SOM) reported strong sales in the US during the quarter (+24% over prior year), combined with ongoing strong Q4 growth in Europe (+20.6%), resulted in record total group unit quarterly sales of 19,859 units (+24.2%). Total device sales for the FY17 stood at 68,100 units. Unaudited quarterly group revenues grew by 22%

Read more

One technology stock doing well – Nearmap Ltd

Launch of NZ capture program and first commercial sale: NEA has completed a one-off capture of New Zealand’s main economic areas during the period, and has already secured the first commercial sales of the imagery to its Australian customers. The pilot capture program was completed in March and covers approximately 72% of the New Zealand population. Further, this pilot program

Read more

BNC210 BNC210 data demonstrates improved efficacy and faster recovery levels

BNC210 data demonstrates improved efficacy and faster recovery levels: BNC210 has demonstrated efficacy in the contextual fear-conditioning extinction paradigm in C56BL6 mice where it significantly enhanced fear extinction, reducing fear behavior, while diazepam (Valium) demonstrated an inhibitory effect resulting in prolonged fear behavior. In humans, BNC210 treatment reduced the emotional impact of a CCK-4 induced panic attack. Individuals who suffered

Read more

Launch of NZ capture program and first commercial sale: NEA has completed a one-off capture of New Zealand’s main economic areas during the period.

Launch of NZ capture program and first commercial sale: NEA has completed a one-off capture of New Zealand’s main economic areas during the period, and has already secured the first commercial sales of the imagery to its Australian customers. The pilot capture program was completed in March and covers approximately 72% of the New Zealand population. Further, this pilot program

Read more

Recently, Bionomics Limited BNC210 data demonstrates it as a novel treatment

BNC210 data demonstrates it as a novel treatment: Recently, Bionomics Limited (ASX: BNO) presented its BNC210 data at the Society of Biological Psychiatry Annual Convention in May 2017 in San Diego, CA. The data highlights a successful Phase 2 double-blinded, placebo controlled clinical trial in Generalized Anxiety Disorder (GAD) patients evaluating the effects of BNC210 on task-related brain activity and

Read more

Three Biotech stocks – Bionomics, Mesoblast & CSL

BNC210 data demonstrates it as a novel treatment: Recently, Bionomics Limited (ASX: BNO) presented its BNC210 data at the Society of Biological Psychiatry Annual Convention in May 2017 in San Diego, CA. The data highlights a successful Phase 2 double-blinded, placebo controlled clinical trial in Generalized Anxiety Disorder (GAD) patients evaluating the effects of BNC210 on task-related brain activity and

Read more
« Older Entries